The future of targeting FLT3 activation in AML
Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-
like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid
leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations
were identified as viable therapeutic targets, and FLT3 tyrosine-kinase inhibitors (TKIs) have
been in development for the last decade with steadily increasing potency. However, FLT3-
mutated AML often acquires resistance to the growing armamentarium of FLT3 inhibitors …
like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid
leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations
were identified as viable therapeutic targets, and FLT3 tyrosine-kinase inhibitors (TKIs) have
been in development for the last decade with steadily increasing potency. However, FLT3-
mutated AML often acquires resistance to the growing armamentarium of FLT3 inhibitors …
以上显示的是最相近的搜索结果。 查看全部搜索结果